Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  SpringWorks Therapeutics, Inc.    SWTX

SPRINGWORKS THERAPEUTICS, INC.

(SWTX)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
01/11/2021 01/12/2021 01/13/2021 01/14/2021 01/15/2021 Date
65.71(c) 66.9(c) 67.18(c) 74.64(c) 79.8(c) Last
318 840 545 775 397 539 617 691 539 540 Volume
-1.17% +1.81% +0.42% +11.10% +6.91% Change
More quotes
Financials
Sales 2020 21,0 M - 15,5 M
Net income 2020 -44,9 M - -33,0 M
Net cash position 2020 362 M - 267 M
P/E ratio 2020 -75,5x
Yield 2020 -
Sales 2021 - - -
Net income 2021 -104 M - -76,9 M
Net cash position 2021 261 M - 192 M
P/E ratio 2021 -37,5x
Yield 2021 -
Capitalization 3 825 M 3 825 M 2 815 M
EV / Sales 2020 165x
EV / Sales 2021 -
Nbr of Employees 71
Free-Float 78,4%
More Financials
Company
SpringWorks Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on acquiring, developing and commercializing medicines for patient suffering from rare diseases and cancer. The Company has a portfolio of small molecule targeted oncology product candidates and other programs addressing genetically defined cancers. Its provides Nirogacestat, which is an oral, small molecule gamma... 
More about the company
Notations Surperformance© of SpringWorks Therapeutics, Inc.
Trading Rating : Investor Rating : -
More Ratings
All news about SPRINGWORKS THERAPEUTICS, INC.
01/05SPRINGWORKS THERAPEUTICS : to Present at the 39th Annual J.P. Morgan Healthcare ..
AQ
2020SPRINGWORKS THERAPEUTICS : HC Wainwright Adjusts SpringWorks Therapeutics' Price..
MT
2020SPRINGWORKS THERAPEUTICS : Barclays Adjusts Price Target for SpringWorks Therape..
MT
2020SPRINGWORKS THERAPEUTICS : Names Chief Operating Officer
MT
2020SPRINGWORKS THERAPEUTICS, INC. : Change in Directors or Principal Officers, Othe..
AQ
2020SpringWorks Therapeutics Announces Executive Leadership Promotions
GL
2020SPRINGWORKS THERAPEUTICS : to Participate in the Evercore ISI HealthCONx Confere..
AQ
2020SPRINGWORKS THERAPEUTICS : to Participate in the Evercore ISI HealthCONx Confere..
AQ
2020SpringWorks Therapeutics to Participate in the Evercore ISI HealthCONx Confer..
GL
2020SPRINGWORKS THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Rece..
AQ
2020Wedbush Adjusts Price Target for SpringWorks Therapeutics to $76 From $50, Ma..
MT
2020SPRINGWORKS THERAPEUTICS, INC. : quaterly earnings release
2020SpringWorks Therapeutics Posts Narrower Q3 Net Loss, But Misses Analysts' Exp..
MT
2020SPRINGWORKS THERAPEUTICS : 3Q Earnings Snapshot
AQ
2020SPRINGWORKS THERAPEUTICS : Reports Third Quarter 2020 Financial Results and Rece..
AQ
More news
News in other languages on SPRINGWORKS THERAPEUTICS, INC.
2020SPRINGWORKS THERAPEUTICS, INC. : Veröffentlichung des Quartalsergebnisses
2020SPRINGWORKS THERAPEUTICS, INC. : publication des résultats trimestriels
More news
Analyst Recommendations on SPRINGWORKS THERAPEUTICS, INC.
More recommendations
Chart SPRINGWORKS THERAPEUTICS, INC.
Duration : Period :
SpringWorks Therapeutics, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends SPRINGWORKS THERAPEUTICS, INC.
Short TermMid-TermLong Term
TrendsBullishBullishBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 6
Average target price 83,20 $
Last Close Price 79,80 $
Spread / Highest target 9,02%
Spread / Average Target 4,26%
Spread / Lowest Target -4,76%
EPS Revisions
Managers and Directors
NameTitle
Saqib Islam Chief Executive Officer & Director
Daniel S. Lynch Chairman
Badreddin Edris Chief Operating Officer
Francis I. Perier Chief Financial Officer
Stephen P. Squinto Director, Head-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
SPRINGWORKS THERAPEUTICS, INC.10.04%3 825
GILEAD SCIENCES, INC.8.70%79 386
VERTEX PHARMACEUTICALS-4.57%58 652
REGENERON PHARMACEUTICALS7.21%54 665
WUXI APPTEC CO., LTD.3.52%52 469
BEIGENE, LTD.33.52%31 458